Potential Applications and Challenges in Front of Brain Biomarkers
Biomarkers are called as a measurable indicator which is used to identify particular disease. Additionally, they are used for evaluation of the most effective therapeutic regime for particular or drug target identification. In the field of neuroscience, biomarker plays an essential role in the identification of a number of neurological disorders and abnormalities. Biomarkers have many useful applications in health care, including disease prevention and detection, individual disease risk determination and disease monitoring.
The Study focuses on leading industry players such as, Advanced Brain Monitoring, Electrical Geodesics, F. Hoffmann-la Roche Ltd, Johnson And Johnson, Seimens Healthnineers, Brainscope, Ge Healthcare, Lifesign Llc., Natus Medical, Neurovista
Biomarkers refer to a wide range of measurements that capture what happens in a cell or organism at a given moment. Biomarkers are objective medical signs (as opposed to symptoms reported by patients) used to measure the presence or progression of a disease or the effectiveness of treatment. Biomarkers can have molecular, histological, radiologic or physiological properties. Examples of biomarkers include everything from blood pressure and heart rate to basic metabolic studies and X-ray discovery to complex histological and genetic testing of blood and other tissues. Biomarkers are measurable and do not define a person's feel or function.
Many biomarkers such as heart rate, urine test, and blood lead level are commonly used and well studied. With advances in genomics and other advances in molecular biology, new biomarker research has entered a promising era with the potential for early diagnosis and effective and personalized treatment of many diseases. In clinical trials, biomarkers act as intermediate markers of the disease and help determine if a particular therapy is effectively treating the disease. A more common approach to using endpoints such as quality of life or mortality in clinical studies can accumulate sufficient data both in time and in cost. Using a biomarker-centric approach can shorten clinical trial times and accelerate product development and regulatory approvals.